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Abstract
Background: Chemo-radiotherapy, a combination of chemotherapy and radiotherapy, is the most
frequent treatment for patients with esophageal cancer. In the process of radiotherapy, the
radiosensitive cancer will become a radio-resistant one.
Methods: In order to detect the chemotherapeutic drug sensitivity in radio-resistant cancer cells
and improve the therapy efficiency, we firstly established a radio-resistant esophageal cancer cell
model (referred to as EC109/R) from the human esophageal squamous cell carcinoma cell line
EC109 through fractionated irradiation using X-rays. The radio-sensitivity of EC109/R cells was
measured by clonogenic assay. To detect the drug sensitivity for EC109/R compared to its parent
cells, we employed MTT method to screen the effectiveness of five different drugs commonly used
in clinical therapy. The ratio of apoptosis was examined by flow cytometry.
Results:  EC109/R cells were more sensitive to 5-fluorouracil, doxorubicin, paclitaxel and
etoposide, but tolerant to cisplatin compared to its original cells.
Conclusion: Our study implies that fractionated irradiation induced radio-resistant esophageal
cancer cell is more sensitive to certain kind of chemotherapeutic drugs. It provides evidence for
choosing the sequence of radiotherapy and chemotherapy in esophageal cancer.
Background
Esophageal squamous cell carcinoma (ESCC) has com-
manded increased attention in the past three decades
because of changing epidemiologic patterns and
expanded treatment options [1-4]. Worldwide, esopha-
geal cancer is the sixth leading cause of cancer death, and
its 5-year survival rate in the United States is 14.9%, being
responsible for 4% of all cancer deaths annually. The age-
standardized incidence rate in China was the highest in
the world. Surgical treatment is the mainly way for local-
ised esophageal carcinoma (stage I-III), but is very limited
effective for stage III [5]. Patients undergoing surgery
alone had a median survival ranging from 13 to 19
months and a 5-year survival rate of 15% to 24%.
The introduction of adjuvant chemo- and radiotherapy
has improved the prognosis of patients with ESCCs, par-
ticularly those with high potential for lymph node metas-
tasis [6,7]. Radiotherapy in particular has played a key role
in the control of tumor growth in esophageal cancer
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patients. This mode of therapy is considered to improve
resection rates, increase survival time, and decrease lymph
metastases. However, the 5-year survival rate with conven-
tional doses of radiation alone is 0% to 10% [8]. One of
the reasons for this low survival rate is the insensitivity of
esophageal cancer to radiotherapy, which decreases the
ability to cure or delay progression of disease in these
patients. Recently, chemo-radiotherapy, a combination of
chemotherapy and radiotherapy, is the most frequent
treatment for patients with esophageal cancer [9-12], and
a complete histopathological response is achieved in
20%–40% of cases. This combination therapy has signifi-
cantly improved median survival and reduced late
relapses in patients with ESCCs. Therefore, suitable chem-
otherapy agents for esophageal cancer, especially for
radio-resistant esophageal cancer are urgently needed.
The purpose of our experiment is to detect the chemother-
apeutic drug sensitivity in radio-resistant cancer cells and
improve the therapy efficiency. In the present study, we
first established a radio-resistant cell model EC109/R
from the human ESCC cell line EC109, by fractionated
irradiation using X-rays. Then the efficiency of chemother-
apeutic drug, cisplatin, 5-fluorouracil, doxorubicin, pacli-
taxel, or etoposide, was screened in EC109 and EC109/R
cells.
Methods
Cell line and cell culture
EC109 cells, a well differentiated human ESCC cell line,
were provided by Cancer Institute and Hospital, Chinese
Academy of Medical Sciences. Cells were maintained in
Dulbecco's modified Eagle's medium (DMEM, GIBCO,
USA) containing 10% heat-inactivated fetal bovine serum
(FBS, GIBCO), 100 U/ml penicillin, 100 U/ml streptomy-
cin and 2 mM L-glutamine at 37°C in a humidified
atmosphere of 5% CO2. Cells were passaged every 2–3
days to maintain exponential growth.
Chemotherapeutic Agents
Cisplatin, 5-fluorouracil, doxorubicin, paclitaxel and
etoposide were of analytical grade and were purchased
from Sigma-Aldrich. They were dissolved in normal saline
at various concentrations. Drug treatment involved con-
tinuous exposure to the compounds.
Establishment of radio-resistant cell line
The method for establishing radio-resistant cell line by
fractionated irradiation has been described previ-
ously[13]. Briefly, the cell line was first grown to approxi-
mately 60% confluence in 25-cm2 culture flasks. Cells
were irradiated with 10 Gy of X-ray irradiation, from a lin-
ear accelerator (6-MV X-ray), at a rate of 3 Gy/min. One
cm thick of tissue-equivalent bolus was placed on top of
the plate to ensure homogeneity. And then cells were
returned to the incubator. When they reached approxi-
mately 60% confluence, the cells were again irradiated
with 10 Gy of X-ray. The fractionated irradiations were
continued until the total concentration reached 80 Gy.
The radio-resistant cell subline was then established. The
parental cells were subjected to identical trypsinization,
replating, and culture conditions, but were not irradiated.
For all assays on irradiated cells, there was at least a four-
week interval between the last 10 Gy fractionated irradia-
tion and the experiment.
Assay for radiosensitivity
Cell survival after X-ray irradiation was measured by clo-
nogenic assay. Cells were plated in six-well culture plates,
and were irradiated at different concentration ranging
from 0 to 12 Gy. The appropriate plating density was
aimed to produce 20–100 surviving colonies in each well.
These cells were incubated at 37°C for 10–14 days (three
wells in each radiation concentration). After fixation with
acetic acid-methanol (1:4) and staining with diluted crys-
tal violet (1:30), colonies consisting of 50 cells or more
were counted under a light microscope. The triplicate col-
onies were averaged and divided by initial seeded cells to
yield survival rate of clones for each concentration, and
the surviving fraction was determined. All survival curves
represent at least three independent experiments.
Detection of apoptotic cells
Apoptosis was evaluated using the Annexin V-FITC Apop-
tosis Detection Kit (BD Biosciences Pharmingen, San Jose,
CA, USA) followed by FACS analysis. Cells were treated
with trypsin-EDTA in PBS at pH 7.5, washed with normal
medium and cold PBS, and then resuspended in 1× bind-
ing buffer. Five μl of annexin V and ten μl of propidium
iodide were added to the cells, vortexed, and incubated for
15 minutes in the dark. Finally, 400 μl of 1× binding
buffer was added, and samples were evaluated by flow
cytometry.
MTT cell viability assay
Drug-induced cytotoxicity was evaluated by conventional
MTT cell viability assay as previously reported [14,15].
Briefly, 1 × 104/well EC109 or EC109/R cells were seeded
in 96-well plates and cultured in DMEM media supple-
mented with 10% FBS for 8 h. They were exposed to vari-
ous concentrations of cisplatin (3.33–63.3 μM), 5-
fluorouracil (0.07–4.93 mM), doxorubicin (0.53–7.36
μM), paclitaxel (3.12–100 nM) or etoposide (1–16 μM)
for 48 h in a CO2 incubator. Ten μl of 5 g/L 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
solution was added to each well for 4 h at 37°C. Subse-
quently the formazan crystals were solubilized with 100
μl of 10% sodium dodecyl sulfate (SDS) in 0.01 M HCl for
24 h. Absorbance at 570 nm relative to a reference wave-
length of 630 nm was determined with a microplateJournal of Experimental & Clinical Cancer Research 2009, 28:68 http://www.jeccr.com/content/28/1/68
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reader (Bio-rad 680, Bio-rad, USA). The concentrations
resulting in 50% inhibition of cell growth (IC50 values)
were calculated.
Statistical analysis
A statistical analysis was performed using two-tailed Stu-
dent's t-test to assess the statistical significance of treated
groups versus control groups. The results with P-values of
less than 0.05 were considered to be statistically signifi-
cant.
Results
Establishment of cell subline resistant to irradiation
The EC109 cells were treated repetitively with 10 Gy of X-
ray irradiation, with about 20 days recovery allowed
between each fraction until the total concentration
reached 80 Gy. The radio-resistant cells were named
EC109/R. The clonogenic assay was used to analyze their
radiosensitivity after 0–12 Gy irradiation. Figure 1 shows
the survival curves of parent and radio-resistant cells. Sur-
viving fractions are shown in Table 1. The subline EC109/
R was more radio-resistant to irradiation than the parental
cell line EC109. Therefore, we considered the subline
EC109/R as a radio-resistant cell line and the radio-resist-
ant subline maintained a relative radio-resistant pheno-
type for at least two months after cessation of fractionated
irradiation (data not shown). For the following assay on
EC109/R cells, there was a six-week interval between the
last 10 Gy fractionated irradiation and the experiment.
Cell proliferation assay
To assess cell proliferation of EC109/R, cell viability was
determined by MTT assay. Aliquots of 2 × 103/well EC109
or EC109/R cells were cultured in 96-well plates for 0, 24,
48, and 72 h. The absorbance intensity of the MTT prod-
uct was detected. As shown in Figure 2, there was no sig-
nificant difference in cell growth after three repetitive
treatments between EC109 and EC109/R (P > 0.05). Each
point in figure 2 represents the mean ± SD of triplicate
experiments.
Irradiation-induced apoptosis in EC109/R cells
The apoptosis induced by 12 Gy irradiation was detected
with Annexin V-FITC staining in cell lines EC109 and
EC109/R. A significant difference was recognized between
EC109 and EC109/R. As shown in figure 3B, about 1%–
2% apoptosis was found in the control groups. In the radi-
ation-treatment groups, the rate of apoptosis in EC109/R
cells compared with EC109 cells was 6.81% ± 0.78% com-
Radiation cell survival curves for EC109 and EC109/R cells Figure 1
Radiation cell survival curves for EC109 and EC109/R 
cells. The colony formation assay was described in Materials 
and methods. Data represent means with standard deviation 
(SD) from three independent experiments. There was a sig-
nificant difference in surviving fraction between parent and 
radio-resistant cells (p < 0.05).
Table 1: Comparison of surviving fraction between EC109 and 
radio-resistant EC109/R cells exposed to various radiation 
concentration
Cell line Radiation concentration
4 Gy 8 Gy 12 Gy
EC109 0.2545 ± 0.023 0.01493 ± 0.0018 0.00038 ± 0.00012
EC109/R 0.3197 ± 0.043 0.02209 ± 0.0033 0.00122 ± 0.0004
p-value 0.032522 0.035813 0.037994
Values reflect mean ± standard deviation (SD).
Cell proliferation assay of EC109 and EC109/R cells Figure 2
Cell proliferation assay of EC109 and EC109/R cells. 
Cells were cultured in 96-well plates for 0, 24, 48 and 72 h. 
Cell viability was determined by MTT assay. Each point rep-
resents the mean ± SD of triplicate experiments (p > 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:68 http://www.jeccr.com/content/28/1/68
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pared with 11.24% ± 1.21% at 48 h after treatment with
12 Gy irradiation (P < 0.05). Thus, the acquirement of
radio-resistance was reflected in a reduced apoptotic rate.
Cytotoxicity of cisplatin, 5-fluorouracil, doxorubicin, 
paclitaxel or etoposide on radio-resistant EC109/R cells
To examine if cellular resistance to ionizing radiation also
causes cross-resistance to the chemotherapeutic agents,
the effects of cisplatin, 5-fluorouracil, doxorubicin, pacli-
taxel and etoposide on the growth of EC109 or EC109/R
cells were evaluated by determining cell viability using
MTT assay. The dose-effect curves and IC50s to different
treatment are shown in figure 4 and table 2. Compared
with the parent cell line EC109, the IC50 value of EC109/
R cells was 1.75-fold for cisplatin, 0.324-fold for 5-fluor-
ouracil, 0.44-fold for doxorubicin, 0.64-fold for paclitaxel
and 0.81-fold for etoposide. EC109/R cells were more sen-
sitive than parental cells to 5-fluorouracil, doxorubicin,
paclitaxel and etoposide. But the sensitivity of EC109/R to
cisplatin decreased. In addition, the numbers of apoptotic
cells were also determined by Annexin V staining followed
by FACS analysis, which showed the same results (Figure
5). Radio-resistance increased sensitivity to chemothera-
peutic drugs of 5-fluorouracil, doxorubicin, paclitaxel and
etoposide significantly. But the radio-resistant subline was
more resistant to cisplatin than the parent cell line EC109.
Discussion
Ionizing radiation (IR) is a potent agent in enhancing
tumor control of locally advanced cancer and has been
shown to improve disease-free and overall survival in sev-
eral entities. Approximately 50%–70% of all cancer
patients receive radiotherapy during their treatment.
Advances in tumor imaging and physical targeting of IR
and optimization of IR delivery schedules from single
treatments to continuous irradiation have yielded signifi-
cant improvements in patient outcome [16]. Nonetheless,
many tumors are poorly controlled by radiotherapy
alone.
Radio-resistance is an obstacle in cancer therapy and
affects the curability of patients. Chronic exposure of cells
Irradiation-induced apoptosis in EC109 and EC109/R cells Figure 3
Irradiation-induced apoptosis in EC109 and EC109/R cells. Cells (1 × 106 each) were seeded in 60-mm dishes and incu-
bated for 48 h after treatment with 12 Gy irradiation. (A)Annexin V-FITC and PI (propidium iodide) staining was performed, 
followed by FACS analysis. (B) The percentage of apoptotic cells was counted (Figure 3A, areas 2 and 3). Similar results were 
obtained in three independent experiments. Errors bar represent the standard error of the mean (p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:68 http://www.jeccr.com/content/28/1/68
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to IR induces an adaptive response that results in
enhanced tolerance to the subsequent cytotoxicity of IR
[17]. In the present study, radio-resistant subline EC109/
R was obtained by exposing the human ESCC cell line
with 80 Gy of fractionated X-rays over an 8-month period.
This results in a statistically significant decreased in the
radiosensitivity of the exposed subline as messured by clo-
nogenic assay. But the growth of EC109/R was similar to
that of the parental cell line (Figure 2). One explanation
for the increased radio-resistance might be an adaptive
response to the selective pressure of repeated radiation.
We observed that the radio-resistant subline maintained a
radio-resistant phenotype for at least 2 months after cessa-
tion of fractionated irradiation in the absence of further
treatment (data not shown).
Over the past several years, it has become increasingly evi-
dent that esophageal cancer is a disease that is potentially
sensitive to chemotherapy. Recent data suggest that multi-
modal therapy is superior to single chemotherapy.
Chemo-radiotherapy can be delivered as a definitive local
therapy without surgery in the treatment of esophageal
cancer [10]. The survival rates for chemo-radiation at 5
and 8 years were 32% and 22%, respectively. However,
the optimal chemotherapy for advanced esophageal can-
cer remains unsettled, and there is no single standard reg-
imen. The most common chemotherapy agents used in
conjunction with radiation have been cisplatin, 5-fluor-
ouracil and docetaxel. Several new chemotherapy agents
are being tested in combination with radiation, but the
best chemotherapy remains to be determined.
The fate of irradiated cells is believed to be controlled by
the network of signaling elements that lead to different
modes of cell death or survival. Many stress-responsive
genes are inducible by IR [18,19]. These radiation-induci-
ble genes are believed to have effects on the chemosensi-
tivity of tumor cells [13,20]. To determine the correlation
between radio-resistance and sensitivity to chemothera-
peutic drugs in esophageal cancer cells, we then analyzed
the chemosensitivity of EC109 and EC109/R cells with
chemotherapeutic drugs cisplatin, 5-fluorouracil, doxoru-
bicin, paclitaxel or etoposide. EC109/R, which survived
80 Gy irradiation, became more sensitive to different con-
centrations of 5-fluorouracil, doxorubicin, paclitaxel and
etoposide, but maintained tolerance to cisplatin, as
assessed by MTT assay (Figure 4). These findings suggest
that cellular resistance to ionizing radiation have effects
on the chemotherapeutic drug sensitivity in esophageal
cancer cells.
Several genes associated with cellular sensitivity to anti-
cancer drugs have been selected for esophageal cancer.
They were B4GALT5 (UDP-Gal: βGlcNAc β1,4-galactosyl-
transferase, polypeptide 5 gene), UGCG (UDP-glucose
Sensitivity of EC109 and EC109/R cells to cisplatin, 5-fluor- ouracil, doxorubicin, paclitaxel or etoposide Figure 4
Sensitivity of EC109 and EC109/R cells to cisplatin, 5-
fluorouracil, doxorubicin, paclitaxel or etoposide. 
EC109 or EC109/R Cells were exposed to various concen-
trations of cisplatin, 5-fluorouracil, doxorubicin, paclitaxel or 
etoposide for 48 h, and then the viability was calculated using 
MTT assay. Each point represents the mean ± SD of triplicate 
experiments (p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:68 http://www.jeccr.com/content/28/1/68
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ceramide glucosyltransferase gene), and XBP1 (X-box
binding protein 1 gene) for 5-fluorouracil, NRCAM (neu-
ronal cell adhesion molecule gene) for doxorubicin,
ARFRP1 (ADP-ribosylation factor related protein 1 gene),
IFITM1 (interferon induced transmembrane protein 1
gene), KIAA0685, and SIPA1L2 (signalinduced prolifera-
tion-associated 1 like 2 gene) for cisplatin [14]. Fraction-
ated irradiation might induce cellular sensitivity related
gene and protein expression in human tumor cell lines.
The fact that drug sensitivity is determined by multiple
genes required a better understanding of the intricate net-
work of the selected genes in the expression levels.
Fractionated radiation treatment has also been reported to
cause drug resistance in ovarian carcinoma cells [21] and
ascites tumor cells [22]. It can induce functionally relevant
multidrug resistance gene and protein expression in human
tumor cell lines [13]. There are multiple factors that con-
tribute to cisplatin resistance, but alterations of DNA repair
processes have been known for some time to be important
in mediating resistance [23,24]. The most important DNA
repair pathways involved in the cisplatin response are
nucleotide excision repair (NER) and mismatch repair
(MMR). MSI, which results from disorder of the MMR sys-
tem and loss of MLH1 protein, is frequently induced during
cisplatin-based chemotherapy [25]. Data have shown that
suppression of ERCC1 expression enhances or restores cis-
platin sensitivity, and combination of p53 inactivation and
MMR deficiency results in cisplatin resistance [26]. Moreo-
ver, enhancement of P-gp and MRP1 after irradiation was
accompanied by a cisplatin-resistance phenomenon [13].
Our results are still preliminary, and further investigations
are required to understand the mechanisms of the
increased or decreased drug sensitivity in the radio-resistant
cell line. As a next step, in vivo experiments would be neces-
sary to confirm the relevance for radio-chemotherapy of
cancer. A detailed understanding of the mechanisms of
radiation-induced chemosensitivity may prove very helpful
for choosing the sequence of radiotherapy and chemother-
apy in esophageal cancer.
Apoptotic changes in EC109 and EC109/R cells treated with different drugs Figure 5
Apoptotic changes in EC109 and EC109/R cells treated with different drugs. EC109 and EC109/R cells treated with 
different drugs (10 μM cisplatin, 1000 μM 5-fluorouracil, 0.6 μM doxorubicin, 0.025 μM paclitaxel or 10 μM etoposide) for 48 
hours were harvested by trypsinization and subjected to annexin V/propidium iodide apoptosis detection assay using a FACS 
flow cytometer. The percentage of apoptotic cells was counted (Figure 3A, areas 2 and 3). Similar results were obtained in 
three independent experiments. Errors bar represent the standard error of the mean (p < 0.05).
Table 2: Comparison of the cytotoxic effects of cisplatin, 5-fluorouracil, doxorubicin, paclitaxel or etoposideon on parental EC109 and 
EC109/R subline.
IC50(uM)
Cells Cisplatin 5-Fluorouracil Doxorubicin Paclitaxel Etoposide
EC109 10.99 923.8 0.67 0.0263 9.46
EC109/R 19.24 299 0.294 0.0169 7.69
Resistance index* 1.75 0.324 0.44 0.64 0.81
*Resistance index = (IC50 on EC109/R)/(IC50 on EC109)Publish with BioMed Central    and   every 
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Conclusion
Our study demonstrated a significant association between
the cellular radio-resistance and the sensitivity of chemo-
therapeutic drugs in esophageal carcinoma cells. This
result implied that doxorubicin, 5-fluorouracil, paclitaxel
or etoposide will provide a more marked therapeutic
effect for radio-resistant esophageal cancer. It will be
important to confirm these findings and to take them into
account in the development of new treatment sequence
for ESCC.
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